Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

OTIC / Otonomy, Inc. / FIRST MANHATTAN CO - NONE (Passive Investment)

2018-02-09 sec.gov
Schedule 13G   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. n/a )*   Otonomy Inc.  (Name of Issuer)   COMMON (Title of Class of Securities)   68906L105 (CUSIP Number)   Calendar Year 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:        x  Rule 13d-1(b)        o  Rule 13d-1(c)        o  Rul

OTIC / Otonomy, Inc. / FIRST MANHATTAN CO - NONE (Passive Investment)

2018-02-09 sec.gov
Schedule 13G   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. n/a )*   Otonomy Inc.  (Name of Issuer)   COMMON (Title of Class of Securities)   68906L105 (CUSIP Number)   Calendar Year 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:        x  Rule 13d-1(b)        o  Rule 13d-1(c)        o  Rul

OTIC / Otonomy, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* OTONOMY, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L105 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of thi

OTIC / Otonomy, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* OTONOMY, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L105 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of thi

OTIC / Otonomy, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us68906l1052_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) OTONOMY INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 68906L105 -------------------------------------------------------- (CUSIP Number) December 31, 2017 -------------------------------------------------------- (

OTIC / Otonomy, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us68906l1052_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) OTONOMY INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 68906L105 -------------------------------------------------------- (CUSIP Number) December 31, 2017 -------------------------------------------------------- (

OTIC / Otonomy, Inc. SC TO-I/A

2018-01-22 sec.gov
SC TO-I/A     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Amendment No. 1 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934     OTONOMY, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.001 par value (Title of Class of Securities) 68906L105 (CUSIP Number of Class of Securities’ Underlying Common Stock) David A.

OTIC / Otonomy, Inc. FORM 8-K (Current Report)

2018-01-09 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2018     Otonomy, Inc. (Exact name of registrant as specified in its charter)       Delaware   001-36591   26-2590070 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

OTIC / Otonomy, Inc. FORM 8-K (Current Report)

2017-12-22 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2017     Otonomy, Inc. (Exact name of registrant as specified in its charter)       Delaware   001-36591   26-2590070 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

OTIC / Otonomy, Inc. SC TO-I

2017-12-20 sec.gov
SC TO-I     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934     OTONOMY, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror))     Options to Purchase Common Stock, $0.001 par value (Title of Class of Securities)     68906L105 (CUSIP Number of Class of Securities’ Underlying Common Stock)     David A.

BRIEF-Otonomy Inc Immediately Discontinuing Commercial Support For Otiprio

2017-11-27 reuters
* OTONOMY INC - ‍ IS IMMEDIATELY DISCONTINUING COMMERCIAL SUPPORT FOR OTIPRIO WHICH IS EXPECTED TO SIGNIFICANTLY REDUCE FUTURE OPERATING EXPENSES​ (97-2)

OTIC / Otonomy, Inc. FORM 8-K (Current Report)

2017-11-27 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2017     Otonomy, Inc. (Exact name of Registrant as specified in its charter)       Delaware   001-36591   26-2590070 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

Otonomy Gets Another Vote of Confidence from SunTrust

2017-11-13 finance.yahoo
Otonomy Inc (NASDAQ:OTIC) magnetized Street-wide attention after Wednesday's triumphant Phase III home run in Meniere's, leading investors to send the stock racing up 83% in value. SunTrust analyst Edward Nash sees a meaningful value driver ahead by the first quarter of 2018, bullish on Otividex's clinical trajectory ahead. (97-3)

Otonomy's (OTIC) CEO David Weber on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day, ladies and gentlemen. And welcome to the Otonomy Incorporated Third Quarter 2017 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time [Operator Instructions]. As a reminder, this conference call maybe recorded. (125-1)


OTIC : Otonomy Stock Analysis and Research Report

Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIOâ (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement (TTP) surgery in pediatric patients, has achieved positive pivotal trial results in patients with acute otitis externa (AOE), and has completed a successful Phase 2 trial in patients with acute otitis media with tubes (AOMT). OTO-104 is a steroid in development for the treatment of Ménière’s disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière’s disease patients are underway with results expected during the second half of 2017, and a Phase 2 trial has been initiated in patients at risk for cisplatin-induced hearing loss. OTO-311 is a N-Methyl-D-Aspartate (NMDA) receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial with a Phase 2 trial expect...

Click for full article
CUSIP: 68906L105